Immunometabolism during Mycobacterium tuberculosis Infection

Nicole C. Howard, Shabaana A. Khader

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations


Over a quarter of the world's population is infected with Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB). Approximately 3.4% of new and 18% of recurrent cases of TB are multidrug-resistant (MDR) or rifampicin-resistant. Recent evidence has shown that certain drug-resistant strains of Mtb modulate host metabolic reprogramming, and therefore immune responses, during infection. However, it remains unclear how widespread these mechanisms are among circulating MDR Mtb strains and what impact drug-resistance-conferring mutations have on immunometabolism during TB. While few studies have directly addressed metabolic reprogramming in the context of drug-resistant Mtb infection, previous literature examining how drug-resistance mutations alter Mtb physiology and differences in the immune response to drug-resistant Mtb provides significant insights into how drug-resistant strains of Mtb differentially impact immunometabolism.

Original languageEnglish
Pages (from-to)832-850
Number of pages19
JournalTrends in Microbiology
Issue number10
StatePublished - Oct 2020


  • drug resistance
  • immunometabolism
  • macrophage metabolism
  • tuberculosis


Dive into the research topics of 'Immunometabolism during Mycobacterium tuberculosis Infection'. Together they form a unique fingerprint.

Cite this